Exploring an interesting dual functionality of anacardic acid for efficient paclitaxel delivery in breast cancer therapy

Nanomedicine (Lond). 2019 Jan;14(1):57-75. doi: 10.2217/nnm-2018-0138. Epub 2018 Dec 13.

Abstract

Aim: To explore the potential of paclitaxel (PTX)-loaded anacardic acid conjugated hydrophobized gelatin nanoparticles.

Materials & methods: Nanoparticles prepared by nanoprecipitation technique were evaluated for various quality attributes (particle size, % entrapment efficiency) in vitro drug release, MCF-7 cell uptake, cell cytotoxicity, in vivo pharmacokinetics, antitumor efficacy and toxicity.

Results: The nanoparticles (250-300 nm, 74% entrapment efficiency) showed approximately 2.26-fold higher apoptosis index and approximately 5.86-fold reduction in IC50 value compared with PTX in MCF-7 cells. Also, approximately 3.51- and 1.36-fold increase in area under the curve compared with Intaxel® and Nanoxel™ (both from Fresenius Kabi, Gurugram, India) was achieved. Significant tumor burden reduction (∼60%) and reduced toxicity was observed compared with marketed formulations.

Conclusion: The hydrophobized gelatin nanoparticles displayed promising therapeutic potential, paving a new path for efficient PTX delivery.

Keywords: apoptosis; breast cancer; gelatin; hydrophobization; nanoparticle.

MeSH terms

  • Anacardic Acids / chemistry*
  • Animals
  • Antineoplastic Agents, Phytogenic / therapeutic use
  • Apoptosis / drug effects
  • Breast Neoplasms / drug therapy*
  • Cell Survival / drug effects
  • Drug Carriers / chemistry*
  • Drug Compounding / methods
  • Drug Liberation
  • Female
  • Gelatin / chemistry
  • Humans
  • Hydrophobic and Hydrophilic Interactions
  • MCF-7 Cells
  • Nanoparticles / chemistry*
  • Paclitaxel / therapeutic use*
  • Particle Size
  • Rats, Sprague-Dawley
  • Surface Properties

Substances

  • Anacardic Acids
  • Antineoplastic Agents, Phytogenic
  • Drug Carriers
  • anacardic acid
  • Gelatin
  • Paclitaxel